Avelumab plus axitinib combination shows promise

A clinical trial looking at the combination of avelumab plus axitinib for renal cell carcinoma (RCC), JAVELIN Renal 101, has released some positive top-line results, which will be presented at an upcoming medical congress. JAVELIN Renal 101 is a pivotal phase III study with 886 renal cancer patients. As part of a planned interim analysis, […]

read more

Joint statement from the EAU and IKCC about the rejection of the ipilimumab plus nivolumab combination for kidney cancer by the EMA

The European Association of Urology (EAU) Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition (IKCC) have issued a joint statement about the rejection of ipilimumab and nivolumab for kidney cancer by the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP). The EAU are saying that the CHMP’s decision […]

read more

Stereotactic body radiotherapy may improve control of localised kidney cancer

A recent study published in The Journal of Urology this month suggests that stereotactic body radiotherapy (SBRT) may be a safe and effective therapeutic option that could control the growth of localised, small numbers of metastases (oligometastatic) in people with advanced renal cell carcinoma (RCC). Fifty-eight RCC patients, who had undergone surgery and had a maximum […]

read more

Patients are willing to share personal data with the NHS, but not pharma

This blog starts with the results of a survey of 2000 people, 56% of which said they would be happy to share personal data with the NHS if it led to better services. But only 15% of those surveyed said they would be prepared to share personal data with pharmaceutical companies. The blog goes on to […]

read more

Contrast-enhanced ultrasound helps diagnose kidney cancer

A 10-year study presented at an international medical conference in Chicago this week suggests that an enhanced ultrasound scan of the kidney is more accurate than computed tomography and magnetic resonance imaging in predicting cancer. Using microbubbles as a contrast agent, ultrasound can thus eliminate the need for unnecessary biopsies and surgeries in some patients. […]

read more

Adjuvant sunitinib may increase symptoms and reduce quality of life in kidney cancer

A recent article in Annals of Oncology reports new patient-reported outcomes data from the S-TRAC study to suggest that adjuvant sunitinib treatment in patients with a high risk of recurrence of renal cell carcinoma (RCC) was linked to increased symptoms and a worse health-related quality of life (HRQoL) compared with placebo. The S-TRAC study showed that […]

read more

New artificial intelligence technique could help predict how cancer will mutate

New research, published in the journal Nature Methods, describes a new artificial intelligence (AI) technique that could help doctors predict how cancer tumours will mutate, and eventually allow them to personalise each individual’s treatment earlier. The research was conducted at The Institute of Cancer Research (ICR) in London, and has resulted in the development of […]

read more

Robotic partial nephrectomy versus open or laparoscopic partial nephrecotmy

A recent literature review and meta-analysis of worldwide data, published in Journal of Urology, reports that undergoing partial nephrectomy using a robotic surgical approach resulted in outcomes that were mostly superior, or at least as good as, those seen with open or laparoscopic partial nephrectomy. The analysis included data from 33 studies including 20,282 patients. Robotic partial nephrectomy […]

read more

Cabozantinib approved as a first-line treatment option for advanced kidney cancer on the NHS

Today, the National Institute for Health and Care Excellence (NICE) have recommended cabozantinib (Cabometyx) as a new first-line treatment option for people with intermediate- or poor-risk advanced renal cell carcinoma (RCC) for use within NHS England and Wales. Cabozantinib is a once-daily oral tablet which targets multiple pathways involved in the growth of tumours. Cabozantinib has been shown to significantly extend progression free survival compared with […]

read more
Showing 1 to 10 of 363 results
  TOP